Related Experiment Video
Updated: Mar 15, 2026
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
3.4K
Genetic Risk Factors in Venous Thromboembolism
1Department 5, Iuliu Hatieganu University of Medicine and Pharmacy, 8, Victor Babes street, 400012, Cluj-Napoca, Romania. chotoleanu@umfcluj.ro.
Advances in Experimental Medicine and Biology
|September 18, 2016
Summary
Genetic factors significantly contribute to thrombophilia, especially in individuals under 50. Testing for inherited thrombophilia is recommended for specific cases, aiding in anticoagulation management and recurrent thrombosis risk assessment.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Genetic risk factors are crucial in the etiopathogenesis of venous thromboembolism (VTE), particularly in those under 50.
- Approximately half of idiopathic VTE cases have an identifiable inherited risk factor.
- Genetic factors include loss-of-function mutations (e.g., antithrombin, protein C, protein S deficiencies) and gain-of-function mutations (e.g., factor V Leiden, prothrombin G20210A).
Purpose of the Study:
- To review the role of genetic risk factors in thrombophilia and VTE.
- To discuss the classification and detection of inherited thrombophilia.
- To highlight the clinical implications of hereditary thrombophilia testing.
Main Methods:
- Review of genetic risk factors for VTE.
- Classification of mutations associated with thrombophilia.
- Discussion of genome-wide association studies (GWAS) in VTE research.
- Analysis of the impact of hereditary thrombophilia testing on patient management.
Main Results:
- Genetic factors play a key role in VTE, especially in younger individuals.
- Inherited thrombophilia is present in about 50% of first-episode idiopathic VTE.
- Genome-wide association studies have significantly advanced understanding of VTE genetic background.
Conclusions:
- Hereditary thrombophilia testing is indicated only in selected patient groups.
- Testing impacts anticoagulation management in specific scenarios like purpura fulminans in children and VTE risk in pregnant women.
- Detection of hereditary thrombophilia can aid in assessing recurrent thrombosis risk in young patients (<40 years) with a positive family history.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
622
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
622
01:26Varicose Veins I: Introduction
298
Varicose veins, or varicosities, are abnormally dilated and twisted superficial veins caused by venous valve incompetence. This condition commonly affects the lower extremities, especially the saphenous veins, due to the higher pressure from prolonged standing and walking. However, varicosities can also occur in other areas, such as the esophagus, vulva, spermatic cords, and anorectal region.Etiology and typesPrimary varicose veins, often idiopathic, are more common in women due to inherent...
298
01:29Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
93
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
420
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
420
01:27Principles of Pharmacogenetics: Types of Genetic Variants
72
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
72